Senators seek changes to FDA guidance to speed entry of insulin biosimilars

As Eli Lilly announced Monday that it would introduce an authorized generic version of its Humalog insulin at half the original price, four senators on both sides of the aisle are seeking tweaks to recent FDA guidance to speed up the marketing of new biosimilar insulin products.